{
    "nctId": "NCT02950480",
    "briefTitle": "Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial",
    "officialTitle": "Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 4,
    "primaryOutcomeMeasure": "Capsular Thickness",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients who are scheduled to undergo therapeutic or prophylactic mastectomy with immediate placement of tissue expanders and have a strong family history or hereditary cancer\n2. Age \u2265 18 years\n3. Zafirlukast is pregnancy category B. There are no adequate and well-controlled trials in pregnant women. Therefore, the effects of zafirlukast on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception: 2 methods of birth control, prior to study entry ad for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n4. Ability to understand a written informed consent document, and the willingness to sign it\n5. At least 4 weeks post-completion of chemotherapy\n6. Adequate organ function within 14 days start of study start:\n\n   1. Absolute neutrophil count (ANC) \u2265 1.5 X 10\\^9/L\n   2. Hemoglobin (Hgb) \u22659g/dL\n   3. Platelets (plt) \u2265 100 x 10\\^9/L\n   4. Potassium within normal range, or correctable with supplements;\n   5. AST and ALT \u22642.5 x Upper Limit Normal (ULN) or \u22645.0 x ULN if liver tumor is present;\n   6. Serum total bilirubin \u2264 1.5 x ULN\n   7. Serum creatinine \u2264 1.5 x ULN, or 24-hr clearance \u2265 60ml/min\n\nExclusion Criteria:\n\n1. Any significant medical condition, laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study\n2. Currently on a leukotriene inhibitor or used within the past 6 months\n3. Prior chest wall radiation\n4. Pregnant or breastfeeding\n5. Hepatic impairment as defined by:\n\n   \u2022 AST(SGOT) \\> 2.5X institutional ULN and ALT(SGPT) \\> 2.5X institutional ULN\n6. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}